Basic Information
Mavenclad
Regulatory Information
EMEA/H/C/004230
Authorised
August 22, 2017
June 22, 2017
12
May 6, 2025
Company Information
the netherlands
Gustav Mahlerplein 102 1082 MA Amsterdam
Merck Europe BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Mavenclad. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mavenclad. For practical information about using Mavenclad, patients should read the package leaflet or contact their doctor or pharmacist.